{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreiba5trlfscuk3gtm6n55gsnpbsvjxti2ue36k5kjfif7j2ta62pvu",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3mfl4h6dezfz2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreiahxdyvhtwp5r5vs6phe7a2vdlgiggzp7ajumtq4jt3s4pgjr6qti"
    },
    "mimeType": "image/jpeg",
    "size": 208758
  },
  "path": "/news/2026-02-semaglutide-nonarteritic-anterior-ischemic-optic.html",
  "publishedAt": "2026-02-23T20:50:01.000Z",
  "site": "https://medicalxpress.com",
  "tags": [
    "Overweight & Obesity"
  ],
  "textContent": "People with type 2 diabetes starting semaglutide have more than a doubled risk for nonarteritic anterior ischemic optic neuropathy (NAION) versus those starting sodium-glucose cotransporter-2 inhibitors (SGLT2is), according to a brief report published online Feb. 12 in JAMA Ophthalmology.",
  "title": "Semaglutide may increase risk for nonarteritic anterior ischemic optic neuropathy"
}